Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4742759
Max Phase: Preclinical
Molecular Formula: C54H66Cl2N8O11
Molecular Weight: 1074.07
Molecule Type: Unknown
Associated Items:
ID: ALA4742759
Max Phase: Preclinical
Molecular Formula: C54H66Cl2N8O11
Molecular Weight: 1074.07
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(CCCCCCOCCOCCOCCCCCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)c(OC)cc23)c(Cl)cc1Cl
Standard InChI: InChI=1S/C54H66Cl2N8O11/c1-70-45-33-43(39(55)31-40(45)56)60-51-36(34-57)35-58-42-32-47(46(71-2)30-38(42)51)75-25-11-18-63-21-19-62(20-22-63)17-7-3-4-8-23-72-26-28-74-29-27-73-24-9-5-6-14-48(65)59-41-13-10-12-37-50(41)54(69)64(53(37)68)44-15-16-49(66)61-52(44)67/h10,12-13,30-33,35,44H,3-9,11,14-29H2,1-2H3,(H,58,60)(H,59,65)(H,61,66,67)
Standard InChI Key: MKHTUOFMIYFSEP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1074.07 | Molecular Weight (Monoisotopic): 1072.4228 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kargbo RB.. (2020) Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer., 11 (12.0): [PMID:33335652] [10.1021/acsmedchemlett.0c00587] |
Source(1):